

Table 2.1: Review of work done on Tacrolimus.....	27
Table 2.2: Review of work done on Febuxostat.....	39
Table 2.3: Literature Review on Cubosomes for Transdermal Delivery.....	45
Table 2.4: Literature review on nanocarriers loaded microneedles for transdermal permeation.....	47
Table 3.1: Reported analytical methods for TAC and FBX.....	58
Table 3.2: Materials & Equipment employed in analytical method development of TAC.....	60
Table 3.3: Chromatographic condition for HPLC of TAC.....	61
Table 3.4: Formulation prototypes for determination of specificity of analytical methods.....	65
Table 3.5: Chromatographic condition for LC-MS of TAC.....	66
Table 3.6: Materials and Equipment used in analytical method development of FBX.....	68
Table 3.7: Chromatographic condition for HPLC of FBX.....	69
Table 3.8: Mean area of TAC obtained using HPLC.....	75
Table 3.9: Sensitivity evaluation of HPLC method of TAC.....	77
Table 3.10: Intraday and interday precision analysis of HPLC methods of TAC.....	77
Table 3.11: Accuracy evaluation of HPLC methods of TAC by standard addition technique....	78
Table 3.12: Mean area of TAC obtained using LCMS.....	80
Table 3.13: Sensitivity evaluation of LCMS method of TAC.....	81
Table 3.14: Intraday and interday precision analysis of LCMS methods of TAC.....	81
Table 3.15: Accuracy evaluation of LCMS methods of TAC by standard addition technique.....	82
Table 3.16: Peak area data of FBX at 0 and 24 h for calibration and stability.....	83
Table 3.17: Sensitivity evaluation of developed HPLC method of FBX.....	84
Table 3.18: Intraday and interday precision analysis of HPLC methods of FBX.....	85
Table 3.19: Accuracy evaluation of HPLC methods of FBX by standard addition technique.....	86
Table 3.20: Absorbance data of FBX in ACN:MOH (9:1) and Phosphate buffer pH 7.4 at 0 and 24 Hrs for calibration and stability.....	87
Table 3.21: Sensitivity evaluation of UV methods of FBX in ACN:MOH (9:1) and Phosphate buffer pH 7.4.....	89
Table 3.22: Intraday and interday precision analysis of UV spectrophotometric methods of FBX.....	90

Table 3.23: Accuracy evaluation of UV methods of FBX by standard addition technique.....	91
Table 4.1A: Mixture components and their ratio for compatibility evaluation.....	98
Table 4.1B: Mixture components and their ratio for compatibility evaluation.....	98
Table 4.2: Characteristic FT-IR spectrum bands of TAC.....	100
Table 4.3: Characteristic FT-IR spectrum bands of FBX.....	103
Table 5.1: Quality risk assessment criteria for various attributes.....	116
Table 5.2: Composition of checkpoint batches.....	117
Table 5.3: Screening of stabilizers for Tacrolimus.....	122
Table 5.4: Selection of concentration of stabilizer for cubosomes of Tacrolimus.....	123
Table 5.5: Selection of concentration of GMO for cubosomes of Tacrolimus.....	123
Table 5.6: Selection of stirring speed for preparation of cubosomes of Tacrolimus.....	124
Table 5.7: Selection of stirring time for preparation of cubosomes of Tacrolimus.....	124
Table 5.8: Selection of temperature for preparation of cubosomes of Tacrolimus.....	125
Table 5.9: Selection of volume of organic phase for preparation of cubosomes of Tacrolimus.....	125
Table 5.10: Selection of rate of addition of organic phase for preparation of cubosomes of Tacrolimus.....	126
Table 5.11: QTPP and CQA elements with justification for cubosomes of Tacrolimus.....	127
Table 5.12: Qualitative risk assessment of independent variables.....	130
Table 5.13: Various parameters affect the product quality along with their levels for screening by fractional factorial design.....	133
Table 5.14: 2-Level fractional factorial batches suggested by Design Expert 7.0.....	134
Table 5.15: Independent variables along with their level for optimization by 3^2 factorial design.....	137
Table 5.16: Randomized design matrix for 3^2 factorial design.....	137
Table 5.17: Analysis of variance of full quadratic model for % entrapment efficiency.....	138
Table 5.18: Coded coefficient of full as well as reduced quadratic model for % entrapment efficiency.....	139
Table 5.19: Analysis of variance of full quadratic model for vesicle size.....	140
Table 5.20: Coded coefficient of full as well as reduced quadratic model for vesicle size.....	141
Table 5.21: Analysis of variance of full quadratic model for PDI.....	143

Table 5.22: Coded coefficient of full as well as reduced quadratic model for PDI.....	143
Table 5.23: Summary of full quadratic model for all independent variables.....	145
Table 5.24: Criteria for optimization of Tacrolimus loaded cubosomes.....	148
Table 5.25: Levels of independent variables as per the point prediction analysis.....	150
Table 5.26: Levels of responses at 95 % confidence and prediction intervals.....	151
Table 5.27: Results of checkpoint batches obtained using optimized overly plot of Tacrolimus loaded cubosomes.....	151
Table 5.28: <i>In-vitro</i> drug release profile of TAC from drug suspension and prepared cubosomes of TAC.....	157
Table 5.29: Various statistical model for release kinetic with their R ² value.....	158
Table 6.1: Quality risk assessment criteria for various attributes.....	165
Table 6.2: Composition of checkpoint batches.....	167
Table 6.3: Screening of stabilizers for FBX.....	171
Table 6.4: Selection of concentration of stabilizer for cubosomes of FBX.....	172
Table 6.5: Selection of concentration of GMO for cubosomes of FBX.....	173
Table 6.6: Selection of stirring speed for preparation of cubosomes of FBX.....	173
Table 6.7: Selection of stirring time for preparation of cubosomes of FBX.....	174
Table 6.8: Selection of temperature for preparation of cubosomes of FBX.....	174
Table 6.9: Selection of volume of organic phase for preparation of cubosomes of FBX.....	175
Table 6.10: Selection of rate of addition of organic phase for preparation of cubosomes of FBX.....	176
Table 6.11: QTPP and CQA elements with justification for cubosomes of FBX.....	176
Table 6.12: Qualitative risk assessment of independent variables.....	179
Table 6.13: Various parameters affect the product quality along with their levels for screening by fractional factorial design.....	182
Table 6.14: 2-Level fractional factorial batches suggested by Design Expert 7.0.....	183
Table 6.15: Independent variables along with their level for optimization by 3 ² factorial design.....	186
Table 6.16: Randomized design matrix for 3 ² factorial design.....	186
Table 6.17: Analysis of variance of full quadratic model for % entrapment efficiency.....	187

Table 6.18: Coded coefficient of full as well as reduced quadratic model for % entrapment efficiency.....	188
Table 6.19: Analysis of variance of full quadratic model for vesicle size.....	189
Table 6.20: Coded coefficient of full as well as reduced quadratic model for vesicle size.....	190
Table 6.21: Analysis of variance of full quadratic model for PDI.....	192
Table 6.22: Coded coefficient of full as well as reduced quadratic model for PDI.....	192
Table 6.23: Summary of full quadratic model for all independent variables.....	194
Table 6.24: Criteria for optimization of FBX loaded cubosomes.....	197
Table 6.25: Levels of independent variables as per the point prediction analysis.....	199
Table 6.26: Levels of responses at 95 % confidence and prediction intervals.....	200
Table 6.27: Results of checkpoint batches obtained using optimized overly plot of FBX loaded cubosomes.....	200
Table 6.28: <i>In-vitro</i> drug release profile of FBX from drug suspension and prepared cubosomes of FBX.....	206
Table 6.29: Various statistical model for release kinetic with their R ² value.....	207
Table 7.1: Quality risk assessment criteria for various attributes.....	214
Table 7.2: Composition of checkpoint batches for cubosomes of TAC loaded MN Patch.....	215
Table 7.3: Composition of checkpoint batches for cubosomes of FBX loaded MN Patch.....	215
Table 7.4: QTPP elements of fast dissolving MN Patch with their justification.....	218
Table 7.4: Qualitative risk assessment of independent variables.....	220
Table 7.5: Various critical material attributes along with their levels for optimization of cubosomes of TAC loaded MN Patch by 3 ² Factorial Design.....	223
Table 7.6: Randomized design matrix for cubosomes of TAC loaded MN Patch using 3 ² factorial design with its CQA.....	223
Table 7.7: ANOVA of full quadratic model for AFF.....	224
Table 7.8: Coded coefficients of full quadratic model for axial fracture force.....	225
Table 7.9: Summary of full quadratic model for AFF.....	226
Table 7.10: ANOVA of full quadratic model for in-vitro dissolution time.....	229
Table 7.11: Coded coefficients of full quadratic model for in-vitro dissolution time.....	229
Table 7.12: Summary of full quadratic model for in-vitro dissolution time.....	231

Table 7.13: Criteria for numerical and graphical optimizations of cubosomes of TAC loaded MN Patch.....	234
Table 7.14: Levels of independent variables as per the point prediction analysis.....	235
Table 7.15: Levels of responses at 95 % confidence and prediction intervals.....	236
Table 7.16: Results of checkpoint batches obtained using optimized overly plot of MN patch loaded with cubosomes of TAC.....	236
Table 7.17: Various critical material attributes along with their levels for optimization of cubosomes of FBX loaded MN Patch by 3 ² Factorial Design.....	236
Table 7.18: Randomized design matrix for cubosomes of FBX loaded MN Patch using 3 ² factorial design with its CQA.....	237
Table 7.19: ANOVA of full quadratic model for AFF.....	238
Table 7.20: Coded coefficients of full quadratic model for axial fracture force.....	239
Table 7.21: Summary of full quadratic model for AFF.....	240
Table 7.22: ANOVA of full quadratic model for in-vitro dissolution time.....	243
Table 7.23: Coded coefficients of full quadratic model for in-vitro dissolution time.....	244
Table 7.24: Summary of full quadratic model for in-vitro dissolution time.....	245
Table 7.25: Criteria for numerical and graphical optimizations of cubosomes of FBX loaded MN Patch.....	248
Table 7.26: Levels of independent variables as per the point prediction analysis.....	249
Table 7.27: Levels of responses at 95 % confidence and prediction intervals.....	250
Table 7.28: Results of checkpoint batches obtained using optimized overly plot of FBX loaded cubosomes.....	250
Table 7.29: Pore closure kinetic at different time intervals for MN patch loaded with cubosomes of TAC.....	257
Table 7.30: Pore closure kinetic at different time intervals for MN patch loaded with cubosomes of FBX.....	257
Table 7.31: Size and entrapment data of cubosomes after dissolution of MN Patch compare to previous results shown in chapter 5 & 6.....	258
Table 7.31: In vitro release profile of drug from its drug and cubosomes loaded MN patch.....	259
Table 7.32: Various mathematical models and their correlation coefficient values.....	261
Table 8.1: Treatment Map of Cubosomes of TAC and FBX on 3T3 cells.....	269

Table 8.2: Treatment Map of Cubosomes of TAC on RAW 264.7 cells.....	269
Table 8.3: Amount of TAC permeated across Rat skin.....	271
Table 8.4: Ex-vivo drug permeation of TAC across Rat skin.....	272
Table 8.5: TAC distribution profile after 24 hours of permeation study.....	272
Table 8.6: Amount of FBX permeated across Rat skin.....	274
Table 8.7: Ex-vivo drug permeation of FBX across Rat skin.....	275
Table 8.8: FBX distribution profile after 24 hours of permeation study.....	275
Table 8.9: In vitro cell viability data for cubosomes of TAC in 3T3 cells.....	278
Table 8.10: In vitro cell viability data for cubosomes of FBX in 3T3 cells.....	279
Table 8.11: In vitro cell cytotoxicity data for cubosomes of TAC in RAW 264.7 cells.....	280
Table 9.1: Animal grouping for pharmacokinetic study of TAC.....	287
Table 9.2: Animal grouping for pharmacokinetic study of FBX.....	288
Table 9.3: Animal grouping for pharmacodynamic study of TAC.....	289
Table 9.4: Parameters to be investigated for pharmacodynamic study of TAC.....	289
Table 9.5: Animal grouping for pharmacodynamic study of FBX.....	291
Table 9.6: Parameters to be investigated for pharmacodynamic study of FBX.....	291
Table 9.7: Plasma drug concentration of TAC after applying various formulation of TAC.....	292
Table 9.8: Pharmacokinetic parameters (TAC) computed using Kinetica Software.....	294
Table 9.9: Plasma drug concentration of FBX after applying various formulation of FBX.....	295
Table 9.10: Pharmacokinetic parameters (FBX) computed using Kinetica Software.....	296
Table 9.11: Paw volume determination in pharmacodynamic model of RA.....	298
Table 9.12: Determination of body weight change during therapy in pharmacodynamic model of RA.....	299
Table 9.13: Absorbance for preparing calibration plot of calibrator RF.....	300
Table 9.14: Determination of Rheumatoid factor in rat serum.....	300
Table 9.15: Determination of Uric acid level in rat serum.....	302
Table 10.1: Three month stability data of cubosomes and cubosomes loaded MNP.....	307